NEW YORK, Sept. 22 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) today listed the common stock of Hana Biosciences Incorporated, under the ticker symbol HBX. Hana Biosciences, Inc. is a South San Francisco-based biopharmaceutical company that acquires, develops, and commercializes products to advance cancer care. "The American Stock Exchange is proud to welcome Hana Biosciences into our expanding group of biotechnology firms," said John McGonegal, senior vice president of the Amex Equities Group. "We look forward to working with Hana Biosciences to increase its profile among investors and assist its efforts to grow and thrive in today's challenging marketplace." Hana Biosciences Inc has selected Cohen Specialists LLC as its specialist. For further information on HBX and other Amex-listed companies, please visit http://www.amex.com/. The American Stock Exchange(R) (Amex(R)) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 168 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit http://www.amex.com/. DATASOURCE: American Stock Exchange CONTACT: Javier E. David, American Stock Exchange, +1-212-306-1440, Web site: http://www.amex.com/

Copyright